| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-088 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于发行股份及支付现金购买资产并募集配套资金暨 关联交易之部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为向特定对象发行股份；股票认购方式为网下，上市股 数为4,493,210股。 本次股票上市流通总数为4,493,210股。 本次股票上市流通日期为2025 年 7 月 16 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 11 月 25 日出具的《关于同意上海皓元医药股份有限公司向 WANG YUAN（王元）等发行 股份购买资产并募集配套资金注册的批复》（证监许可[2022]3042 号），同意公司向 特定对象 WANG YUAN（王元）、上海源盟企业管理咨询合伙企业（有限合伙）（以 下简称"上海 ...

证券代码：688131 证券简称：皓元医药 公告编号：2025-087 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、关于公司董事辞职的情况说明 上海皓元医药股份有限公司（以下简称"公司"）董事会于近日收到董事 徐影女士提交的辞职报告，因公司内部调整，徐影女士辞去公司第四届董事会 董事职务，同时辞去董事会审计委员会委员职务。辞任后，徐影女士继续在公 司担任其他职务。 徐影女士辞职不会导致公司董事会成员低于法定最低人数，不会影响公司 董事会的正常运行，亦不会对公司的规范运作和日常运营产生不利影响，其辞 职报告自送达公司董事会之日起生效。 二、关于选举职工代表董事的情况说明 为保障公司董事会正常运作，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等法律法规和规范性文件及《上海皓元医药股份有限公司章程》（以下简 称"《公司章程》"）等相关规定，公司于 2025 年 7 月 7 日召开 2025 年第二次职 工代表大会。经全体与会职工表决，选举徐影 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-087 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于选举第四届董事会职工代表董事、董事会审计 委员会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于 2025 年 7 月 7 日召开第四届董事会第八次会议，审议通过了《关于 选举公司董事会审计委员会委员的议案》，现将相关情况公告如下： 根据《公司法》《上市公司章程指引》等相关规定，为进一步完善公司治理 结构，保障规范运作，并结合公司实际情况，选举徐影女士为第四届董事会审 计委员会委员，任期自本次董事会审议通过之日起至第四届董事会任期届满之 日止。除上述调整外，公司第四届董事会审计委员会其他委员保持不变。 一、关于公司董事辞职的情况说明 上海皓元医药股份有限公司（以下简称"公司"）董事会于近日收到董事 徐影女士提交的辞职报告，因公司内部调整，徐影女士辞去公司第四届董事会 董事职务，同时辞去董事会 ...

Core Viewpoint - The legal opinion letter issued by Deheng Shanghai Law Firm confirms that the procedures for the upcoming shareholders' meeting of Shanghai Haoyuan Pharmaceutical Co., Ltd. comply with relevant laws and regulations, ensuring the legitimacy of the meeting and its resolutions [1][4][10]. Group 1: Meeting Procedures - The fourth board meeting of the company was held on June 18, 2025, where the decision to convene the shareholders' meeting was made [4]. - The notice for the shareholders' meeting was published on June 20, 2025, detailing the time, location, agenda, and registration methods, with a record date set for July 1, 2025 [4][5]. - The meeting will be conducted using a combination of on-site and online voting methods, with specific time slots allocated for each voting method [5][10]. Group 2: Qualifications of Participants - The shareholders' meeting is convened by the company's board of directors, which is authorized to do so under the Company Law and the company's articles of association [5][6]. - A total of 75 shareholders and representatives attended the meeting, representing 105,439,641 shares with voting rights, which is a significant portion of the total voting shares [5][6]. - All attending shareholders provided valid identification, and the qualifications of online voters were verified by the Shanghai Stock Exchange's information company [6][10]. Group 3: Voting Procedures and Results - Voting was conducted through both written and online methods, with the counting and monitoring of votes carried out by the lawyers, supervisors, and shareholder representatives [6][10]. - The resolutions passed during the meeting included the cancellation of the supervisory board and amendments to the company's articles of association, with significant support from the voting shareholders [8][9]. - The voting results showed overwhelming approval for the proposed resolutions, indicating strong shareholder support for the company's governance changes [8][9].

表决情况： | 同意 | | | 反对 | | | 弃权 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东类型 | | 比例 | | | 比例 | | 比例 | | | 票数 | | | 票数 | | | 票数 | | | | （%） | | | | （%） | | | （%） | | | 普通股 | 104,720,543 | 99.3180 | 711,309 | 0.6746 | | 7,789 0.0074 | | | | 审议结果：通过 | | | | | | | | | | 表决情况： | | | | | | | | | | 同意 | | | | 反对 | | 弃权 | | | | 股东类型 | | 比例 | | | 比例 | | 比例 | | | 票数 | | | 票数 | | | 票数 | | | | （%） | | | | （%） | | | （%） | | | 普通股 | 104,718,843 | 99.3164 | 711,309 | 0.6746 | | 9,489 0.0090 | | | | 划> ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-086 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 2025年第四次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 7 月 7 日 （二） 股东大会召开的地点：上海市浦东新区张衡路 1999 弄 3 号楼公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 75 | | --- | --- | | 普通股股东人数 | 75 | | 2、出席会议的股东所持有的表决权数量 | 105,439,641 | | 普通股股东所持有表决权数量 | 105,439,641 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 51.07 ...

德恒上海律师事务所 2025 年第四次临时股东大会之 关于上海皓元医药股份有限公司 2025 年第四次临时股东大会 之 见证法律意见书 上海市虹口区东大名路 501 号上海白玉兰广场办公楼 23 楼 电话：021-55989888 传真：021-55989898 德恒上海律师事务所 关于上海皓元医药股份有限公司 2025 年第四次临时股东大会之见证法律意见书 德恒上海律师事务所 关于上海皓元医药股份有限公司 见证法律意见书 德恒 02G20250134-00001 号 致：上海皓元医药股份有限公司 德恒上海律师事务所（以下简称"本所"）接受上海皓元医药股份有限公司 （以下简称"公司"）委托，指派张露文律师、邹孟霖律师（以下合称"本所承 办律师"）出席公司于2025年7月7日下午14点00分在上海市浦东新区张衡路199 9弄3号楼公司会议室召开的2025年第四次临时股东大会（以下简称"本次股东大 会"），就本次股东大会召开的召集和召开程序、召集人及出席会议人员的资格、 会议议案、表决方式和表决程序、表决结果和会议决议等进行见证并出具本法律 意见书。 本所承办律师依据本法律意见书出具日前已经发生或存在的事实和《中 ...

Group 1 - The stock price of Haoyuan Pharmaceutical (688131) closed at 51.89 yuan on July 4, 2025, with an increase of 3.26% and a trading volume of 81,700 shares, resulting in a transaction amount of 420 million yuan [1] - On July 4, the net inflow of main funds was 20.6555 million yuan, accounting for 4.92% of the total transaction amount, while retail investors had a net outflow of 38.5298 million yuan, accounting for 9.18% [1][4] - The company announced a share repurchase and cancellation of 47,725 shares due to the failure of a performance commitment by a related party, resulting in a change in total share capital from 211,609,573 shares to 211,561,848 shares [1][4] Group 2 - The convertible bond "Haoyuan Convertible Bond" will have its conversion price adjusted from 40.58 yuan to 40.59 yuan per share, effective from July 8, 2025, following the share repurchase [2] - The bond will be suspended from conversion starting July 7, 2025, and will resume on July 8, 2025 [2][4] - The company issued 822.35 million yuan of convertible bonds with a maturity of six years, with an initial conversion price of 40.73 yuan per share [2]

Core Viewpoint - The rapid development of the global innovative drug industry has led to a significant opportunity for the CDMO (Contract Development and Manufacturing Organization) sector, with Shanghai Haoyuan Pharmaceutical Co., Ltd. positioning itself as a leader in the ADC (Antibody-Drug Conjugate) niche [1][2]. Group 1: Company Strategy and Market Position - Haoyuan Pharmaceutical has identified ADC as a key area for growth, establishing core competencies and positioning itself in the first tier of CDMO providers in this field [1][2]. - The company has successfully undertaken over 110 ADC projects in 2024, with 12 small molecule products related to ADC having completed FDA filings [2]. - The company reported a revenue of 2.254 billion yuan in 2024, a year-on-year increase of 20.62%, and a net profit of 202 million yuan, up 58.17% year-on-year [2]. Group 2: Technological Advancements - ADC technology, which combines antibodies, linkers, and cytotoxic drugs, allows for targeted cancer treatment, minimizing damage to normal tissues [2]. - Haoyuan Pharmaceutical has developed proprietary technologies in ADC, having been a pioneer in this field since its establishment in 2006 [3]. - The company has collaborated with AI pharmaceutical firms to enhance drug development processes, establishing an AI Drug Exploration Joint Laboratory with East China Normal University [3]. Group 3: International Expansion - The company is actively expanding its international market presence, having serviced numerous ADC "outbound" orders, with nine overseas licensing transactions reported in the first half of the year [4]. - Haoyuan Pharmaceutical has established a CDMO base in Chongqing, which is the largest of its kind in Southwest China, and has passed EU quality audits to facilitate international market expansion [4][5]. - The company has set up business warehousing centers in the US, Europe, and India, serving over 13,000 pharmaceutical companies and research institutions globally [5]. Group 4: Future Prospects - Haoyuan Pharmaceutical is not only focusing on ADC but is also exploring emerging fields such as PDC (Peptide-Drug Conjugates), RDC (Radioisotope-Drug Conjugates), and ApDC (Aptamer-Drug Conjugates) [5]. - The company aims to create a full-chain service model that integrates technology research, industrialization, and global service, thereby establishing competitive barriers [5].

Core Insights - Haoyuan Pharmaceutical (688131) has successfully launched its ADC CDMO base in Chongqing, achieving compliance with EU GMP standards, which positions the company to expand its domestic and international market presence [2] - The ADC sector is entering a golden development period, driven by technological advancements and clinical breakthroughs, with the global ADC market projected to exceed $100 billion by 2032 and a compound annual growth rate (CAGR) of 54.3% in China [3] - Haoyuan Pharmaceutical has established an integrated service platform from R&D to production, becoming a pioneer in the ADC field in China, with significant technological achievements and a strong pipeline of products [4] Industry Development - The ADC market is experiencing rapid growth, with the global market reaching a historical high of $3.9 billion in Q1 2025, and notable products like DS-8201 achieving over $1 billion in quarterly sales [3] - Haoyuan Pharmaceutical has built a "three-in-one" production base in Shanghai, Ma'anshan, and Chongqing, with the Chongqing facility being the largest ADC CDMO platform in Southwest China, enhancing its production capabilities [5] Technological Innovation - The company has developed a unique XDC Payload-Linker CMC integrated service platform, significantly reducing synthesis steps and production costs, exemplified by the synthesis of Erythromycin [4] - By the end of 2024, Haoyuan Pharmaceutical has completed FDA sec-DMF filings for 12 small molecule products related to ADCs, showcasing its strong technical capabilities [4] Collaborative Efforts - Haoyuan Pharmaceutical is actively forming strategic partnerships, including collaborations with AbTis Co., Ltd. for ADC innovation and with Yingbairui for process development and GMP production [7] - The company is also engaging with AI pharmaceutical firms to enhance drug discovery processes through advanced algorithms and data analysis [7] Global Expansion - Since initiating its global strategy in 2015, Haoyuan Pharmaceutical has established business centers in the US, Europe, and India, serving over 13,000 pharmaceutical companies and research institutions [8] - The company services over 95% of domestic ADC export enterprises, reflecting its platform value and customer trust in the industry [8] - Haoyuan Pharmaceutical is also exploring emerging fields such as peptide-drug conjugates (PDC) and radionuclide-drug conjugates (RDC), while leveraging AI to improve drug development efficiency [8]